Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0757
D

Failure to Prevent Duplicate PPI Therapy in a Resident with GERD

Livermore, California Survey Completed on 05-16-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

A deficiency occurred when a resident with a history of GERD, diabetes, kidney disease, and heart issues was prescribed and administered two proton pump inhibitors (PPIs), pantoprazole (Protonix) and omeprazole (Prilosec), at the same time. The resident's medical record showed that Prilosec had been prescribed for GERD and continued after a recent hospitalization, while Protonix was added upon the resident's return from the hospital. Nursing staff did not identify or address the duplicate therapy, and the duplicate medications were not flagged in the electronic medical record system. The Licensed Vocational Nurse acknowledged that Prilosec should have been discontinued and that the physician should have been notified about the duplicate PPI therapy. The facility's consultant pharmacist confirmed that there was no clinical justification for the resident to be on both PPIs simultaneously and that this practice would not provide additional benefit. The facility's policies required ongoing review of medication regimens for indications, doses, duration, and potential adverse consequences, but these procedures were not followed in this case. The medical director was not reached for comment during the survey.

An unhandled error has occurred. Reload 🗙